Autologous cellular therapy
BrainStorm is focused on developing clinical-stage autologous cellular therapy as a potentially transformative approach to treating neurodegenerative diseases.
01
What makes it different
Because the cells come from the patient, there is no donor matching and no immunosuppression - and because they are differentiated rather than genetically modified, the biology stays close to the body’s own repair machinery. BrainStorm has developed a targeted, innovative, proprietary and validated autologous cellular technology platform for the treatment of neurodegenerative diseases.
No donor matching
Cells originate from the patient’s own bone marrow.
Not genetically modified
MSCs are differentiated in culture, not edited.
Delivered to the CNS
Intrathecal injection places cells at the site of damage.
Read next
- 02
MSC-NTF cells
How MSCs are differentiated to secrete high levels of neurotrophic factors - without genetic modification.Read more - Science
The platform, in five parts
Autologous cellular therapy, MSC-NTF cells, cell production, the exosome platform and the intellectual property behind them.Back to Science
BrainStorm's autologous MSC-NTF cell therapy (NurOwn®, debamestrocel) is investigational and has not been approved by the FDA or any other regulatory authority.